Work

A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC).

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps9610

Authors: Maria Gonzalez, Alexander Christopher Jonathan van Akkooi, Thomas Bennett, Sydney Ch'ng, Kerwin Frank Shannon, Michael Alexander Rtshiladze, Richard A. Scolyer, Robert V. Rawson, Monica Osorio, Rony Kapoor, Edward Hsiao, Helen Rizos, Serigne N. Lo, Alexander M. Menzies, Angela M. Hong, Georgina V. Long, Ines Esteves Domingues Pires da Silva

Institutions: Melanoma Institute Australia, The University of Sydney, Royal Prince Alfred Hospital, Chris O’Brien Lifehouse, Royal North Shore Hospital, Macquarie University

Language: English

Topic: Nonmelanoma Skin Cancer Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Bristol-Myers Squibb

OpenAlex ID: W4410805306

FWCI:

Cites:

Cited by:

Related to: 10